Submitted by web@researchtop... on Tue, 09/03/2019 - 11:38
Interview with Ian E Krop, MD, PhD
Track 1:
Case: A patient in her late 40s with ER-positive, HER2-positive, node-positive breast cancer experiences a near complete response after treatment with neoadjuvant doxorubicin, cyclophosphamide, paclitaxel, trastuzumab and pertuzumab (AC-THP)
Track 2:
Choice of neoadjuvant chemotherapy for patients with HER2-positive breast cancer
Track 3:
Pertuzumab toxicity with or without chemotherapy
Track 4:
Management of the axilla in patients with clinically node-positive breast cancer who achieve a pathologic complete response to neoadjuvant systemic therapy
Track 5:
Design and results from the Phase III KATHERINE study evaluating adjuvant T-DM1 versus trastuzumab for patients with HER2-positive early breast cancer and residual disease after neoadjuvant treatment
Track 6:
Perspective on the benefits and risks of T-DM1/pertuzumab versus T-DM1 alone as adjuvant therapy
Track 7:
Benefit of T-DM1 compared to trastuzumab irrespective of the extent of residual disease at surgery in the KATHERINE trial
Track 8:
Clinical implications of the KATHERINE trial results
Track 9:
Results from the Phase III KRISTINE study evaluating neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) versus T-DM1 and pertuzumab for HER2-positive breast cancer
Track 10:
Use of cold caps to reduce the risk of alopecia with chemotherapy
Track 11:
Side-effect profile of T-DM1 in the adjuvant KATHERINE trial
Track 12:
Perspective on the use of neratinib in the post-(neo)adjuvant and metastatic settings
Track 13:
APHINITY: Phase III study evaluating adjuvant pertuzumab in combination with trastuzumab and chemotherapy for HER2-positive early breast cancer
Track 14:
Biomarker analysis of the APHINITY trial: Genomic correlates of response to adjuvant pertuzumab with trastuzumab for HER2-positive breast cancer
Track 15:
Emerging data with immune checkpoint inhibitors in combination with HER2-targeted therapy for HER2-positive breast cancer
Track 16:
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 and pertuzumab: Results from a prospective clinical trial
Track 17:
Changes in HER2 status during disease progression
Track 18:
Case: A woman in her early 60s with de novo ER-positive, HER2-positive metastatic breast cancer (mBC) experiences disease progression in the brain during treatment with T-DM1
Track 19:
Activity of T-DM1 in patients with brain metastases
Track 20:
Efficacy and tolerability of tucatinib for HER2-positive mBC; ongoing Phase II HER2CLIMB study evaluating tucatinib versus placebo, each in combination with capecitabine and trastuzumab
Track 21:
Emerging data with neratinib and capecitabine for patients with HER2-positive breast cancer and brain metastases
Track 22:
Response to CDK4/6 inhibitors in patients with ER-positive, HER2-positive mBC
Track 23:
Case: A woman in her early 30s with HER2-positive mBC receives trastuzumab deruxtecan on a clinical trial after experiencing disease progression on multiple lines of therapy
Track 24:
Results of a Phase I trial of trastuzumab deruxtecan for patients with advanced HER2-positive breast cancer previously treated with T-DM1
Track 25:
Benefits and risks of trastuzumab deruxtecan for advanced HER2-positive breast cancer
Track 26:
Response to trastuzumab deruxtecan in patients with breast cancer and low HER2 expression
Track 27:
Other novel agents and approaches under evaluation for HER2-positive breast cancer
FACULTY
Ian E Krop, MD, PhD
Associate Chief Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Sara Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Santa Monica, California
EDITOR
Neil Love, MD
Research To Practice
Miami, Florida